The FDA's Pharmacy Compounding Advisory Committee (PCAC) met July 2324 to evaluate whether specific peptides, including BPC-157, belong on the 503A Bulks List, which is the FDAs roster of substances eligible for pharmaceutical compounding
However, as with any biologically active compound, medical supervision is essential
Its perfect for those looking to correct a deficiency, increase their energy, or maintain overall health especially if dietary intake is limited
Not a peptide
Based on preclinical (animal and cellular) data only, inhibition of NNMT by 5-Amino-1MQ is theorised to: Raise intracellular NAD+ levels Activate SIRT1 and other sirtuins (proteins linked to metabolic regulation) Reduce fat cell (adipocyte) size and proliferation Improve insulin sensitivity These effects have been demonstrated in mouse models (Neelakantan et al., 2019), but robust human clinical trial data are currently absent
What dose should be given